Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors. - Wikidata - wikimedia - TriplyDB

Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors.

Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors.

http://www.wikidata.org/entity/Q37367593

about

Novel systemic therapy against malignant pleural mesothelioma.Current Status of Marine-Derived Compounds as Warheads in Anti-Tumor Drug Candidates.Amatuximab and novel agents targeting mesothelin for solid tumors.New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.Overexpressed genes in malignant pleural mesothelioma: implications in clinical management.New horizons from immunotherapy in malignant pleural mesothelioma.Fn3 proteins engineered to recognize tumor biomarker mesothelin internalize upon binding.

P2860

Q33890499-5D9ECEE3-3BA6-4713-B3BC-5A65940E2AB8 Q38738155-F28DEC8E-C9FD-4F44-9168-511F848FD723 Q47126660-EA45CBDB-2F4A-4B7B-A662-CD0066A849E3 Q47221234-6D43FB56-1C21-4FF4-AE1A-299BBBBCA103 Q52672878-54DF8ACE-3FB4-4607-9E60-7F9609CD0B48 Q52672888-97E90002-9441-420F-A53B-380B920BF847 Q55257427-A616A00D-4CB4-4A4F-87DB-F1531F1DBA60

P2860

Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors.

http://www.wikidata.org/entity/Q37367593

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors.

@en

Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors.

@nl

type

label

Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors.

@en

Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors.

@nl

prefLabel

Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors.

@en

Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors.

@nl

P1433

Q37367593-C153B398-3CC9-40ED-946E-DCD199755EBC

P1476

Q37367593-3BA38B66-B1CA-4028-9C57-8EB17646C5AA

P2093

Q37367593-05AD267B-4468-44FB-8AC1-E9EBB41D831B

Q37367593-28D02245-02EE-46AF-9F53-ECC38E7B21AA

Q37367593-4320E966-5F13-49EB-AD78-D7D31C48A036

Q37367593-C82DEA86-ABA9-479D-9DAD-FE2EFC48C26D

Q37367593-F0C2B544-CA74-4195-B21C-77A61B8EBBFE

P2860

Q37367593-058C571E-3B14-4DC9-A6AA-84FDE5D9A061

Q37367593-07B75CA2-9394-4F18-B34F-B4D38D4C7139

Q37367593-08E0DEB8-E79F-4463-9FC6-D9F38DD7C7ED

Q37367593-0B96EBE4-D36A-4DF8-AAE3-1F6AE2943768

Q37367593-0E9855D2-F0AF-4EA7-9455-EAF7CD06E3B8

Q37367593-16B22D40-606E-468E-A25E-652B2FEAEBF0

Q37367593-1F7770A6-65F3-48A1-9066-9350898F02F8

Q37367593-220D0795-F263-4540-832E-03ADBC718D1A

Q37367593-227CA555-4DFA-4144-83D2-80F7249417EE

Q37367593-3081BF2B-7CC4-4A74-BEBE-56B5A71C50DA

P304

Q37367593-F49DB833-CB5E-497B-9315-491C0FF99B18

P31

Q37367593-4E73C934-1765-4A7A-8244-25630F159CD4

P356

Q37367593-23835FE1-409B-4B57-BA50-3314010A3F80

P433

Q37367593-1DD04227-C57F-4E12-8F44-DAE04C7D4E03

P478

Q37367593-5D26B2C4-8B30-4963-BD09-ED4B2AF01C7C

P577

Q37367593-2B995710-68E0-4B17-98EA-EB7F5D134C71

P698

Q37367593-9E0CBCD1-74DD-489E-A7D0-EB6DA0B8CF03

P921

Q37367593-4F0A0247-A3EE-4333-B223-0D719DBFCF68

P932

Q37367593-9F5E69B4-F4E4-49C2-ABE3-64F1C19656FE

P356

2212697X03666160218215744

P1433

Clinical cancer drugs

P1476

Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors.

@en

P2093

Babu Subramanyam

http://www.w3.org/2001/XMLSchema#string

Harald Dinter

http://www.w3.org/2001/XMLSchema#string

Nenad Sarapa

http://www.w3.org/2001/XMLSchema#string

Sven Golfier

http://www.w3.org/2001/XMLSchema#string

Xiao-Yan Zhao

http://www.w3.org/2001/XMLSchema#string

P2860

Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion

Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers

A binding domain on mesothelin for CA125/MUC16

Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma

Discovery of new biomarkers for malignant mesothelioma

Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis

Recognition of Mesothelin by the Therapeutic Antibody MORAb-009: STRUCTURAL AND MECHANISTIC INSIGHTS

Advances in anticancer immunotoxin therapy

Mesothelin: a new target for immunotherapy

Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium

P304

76-86

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2174/2212697X03666160218215744

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2016-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27853672

http://www.w3.org/2001/XMLSchema#string

P921

P932

5080863

http://www.w3.org/2001/XMLSchema#string